[Diabetes Trends] Treating Diabetes Beyond A1C: Considerations for Cardiovascular Protection
This webcast will review the safety and efficacy of recent trials for SGLT-2 inhibitors and GLP-1 RAs on cardiovascular outcomes in patients with diabetes. This activity will also explore the impact that diabetes agents with positive CV outcomes have on cardiometabolic markers and how CV outcomes data may impact management of patients with type 2 diabetes.
The target audience for this educational activity is primary care physicians (internal medicine, family practice MD/DOs), nurse practitioners (NPs), and physician assistants (PAs) who practice in a primary care setting.
Review the safety and efficacy of recent trials for SGLT-2 inhibitors and GLP-1 RAs on cardiovascular outcomes in patients with diabetes
Discuss the effects of diabetes agents with positive CV outcomes have on Cardiometabolic markers including lipids, blood pressure, weight, A1C, and hypoglycemia risk
Assess the impact of CV outcomes data for the practical management of patients with type 2 diabetes
Activity Launch Date - 12/20/18
Expiration Date - 12/20/19
The Diabetes Trends webcast series was adapted from a series of live programs presented in the Fall of 2018 in collaboration with the Nurse Practitioner Healthcare Foundation (NPHF). The goal of Diabetes Trends was to foster collaboration, share best practices and provide a forum for peer-to-peer interaction among primary care physicians and advanced practice providers who are actively engaged in the clinical care of diabetes patients.
This activity was originally presented as the fifth session in the Diabetes Trends series. Find other activities from this series on our website:
- [Session 1] Considerations for Advancing Treatment After Metformin
- [Session 2] How to Select and Start Insulin in Patients with Type 2 Diabetes: A Hands-on Demonstration
- [Session 3] Novel Pharmacological Approaches to Treating Post-Prandial Hyperglycemia in Type 2 Diabetes: Fixed-Ratio GLP-1 RA and Basal Insulin Combinations
- [Session 4] Continuous Glucose Monitoring: Implications for Primary Care in Management of Type 2 Diabetes
- [Session 5] Treating Diabetes Beyond A1C: Considerations for Cardiovascular Protection
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome comments about how to better serve your needs.
Copyright© 2018 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.
Jennifer B. Green, MD
Associate Professor of Medicine
Duke University Medical Center
Division of Endocrinology
Jennifer B. Green, MD is an associate professor of medicine in the division of endocrinology, metabolism, and nutrition at Duke University; is a faculty member of the Duke Clinical Research Institute (DCRI); and served as chief of the endocrinology section at the Durham VA medical center from 2003-2017.
Dr. Green’s research has focused primarily upon strategies to predict, prevent, and treat diabetes mellitus. In particular, she is interested in the effects of various interventions to modify glycemic control, dyslipidemia, and hypertension upon cardiovascular and other diabetes-related complications. She has served as an investigator in federally funded clinical trials of type 2 diabetes management including ACCORD, BARI 2D, and GRADE, and is a member of the data and safety monitoring board for the NIDDK consortium of artificial pancreas studies. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She serves as US coordinating center PI and US national representative for the EMPA-Kidney trial. Dr. Green also leads a study team within the DCRI and Duke Data Science groups focused upon utilization of electronic health data to guide and improve medical decision-making in the care of patients with diabetes.
Dr. Green completed her undergraduate and medical degrees at the University of Virginia, her internal medicine residency at the University of North Carolina, and her endocrinology fellowship at Duke University.
Faculty Disclosure Statement
Dr. Green has served on an Advisory Board for Merck, Boehringer Ingelheim, Daiichi, and NovoNordisk. She has performed contracted research for GlaxoSmithKline, Merck, AstraZeneca, and Intarcia.
Planning Committee & Non-faculty Contributors Disclosure Statement
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose in the last 12 months.
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
How To Claim Credit
- Read the learning objectives and faculty disclosures
- Complete the Pre-test
- Participate in the activity
- Complete the Post-test
- Complete Final Evaluation